Bauer Jake 4

What Happened
Jake Bauer, a non‑employee director of Enliven Therapeutics, received a derivative equity award on February 12, 2026: an option covering 17,126 shares granted at $0.00 (no cash paid). The grant is recorded as a derivative acquisition (no immediate proceeds or cash outlay).

Key Details

• Transaction date: 2026-02-12; Form 4 filed: 2026-02-17. Filing appears timely (Feb 16 was a federal holiday).
• Amount: 17,126 shares (derivative option) granted at $0.00. Reported value: $0.
• Shares owned after transaction: not disclosed in this filing.
• Footnote: 100% of the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting or (ii) the date of the 2027 annual meeting, provided Bauer continues as a non‑employee director through the applicable vesting date.
• No immediate exercise or sale reported.

Context
This is a standard director equity grant intended to align management and shareholder interests; because it is an option grant (derivative) the award does not translate into vested common shares until the vesting conditions are met and any exercise requirements are satisfied. Such grants are routine for board members and do not, by themselves, indicate a director buying or selling stock.